Strong genetic evidence supports an imbalance between production and clearance of
amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially …

Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly
failed in clinical trials. Together with numerous reports that amyloid is present in brains from …

Few diagnoses in modern medicine evoke more apprehension in patients and their families
than Alzheimer disease (AD). Defined as a clinical and pathological entity a century ago, the …

Highlights•Lack of success of most anti-amyloid trials in symptomatic AD is attributable in
part to the pathology being too advanced.•Progress in quantifying tau and Aβ in plasma …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Alzheimer disease (AD) is the most common type of dementia, and is currently incurable;
existing treatments for AD produce only a modest amelioration of symptoms. Research into …

Abstract Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab,
antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary …

The identification of amyloid-β precursor protein (APP) pathogenic mutations in familial early
onset Alzheimer's disease (AD), along with knowledge that amyloid-β (Aβ) was the principle …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Advances in the understanding of Alzheimer's disease (AD) pathogenesis provide strong
support for a modified version of the amyloid cascade hypothesis, which is now often …